Get started

Psychedelic

MMED almost at NASDAQHello fellow Bulls, hope you caught the train on MMED and any psychedelic stocks before they left the station, the volatility I witnessed on MMED is quite scary, specially the last 2 days that were a 30% drop. However, the public deal announcement that drove the stock 30% down was a necessary move to get cash. Without cash, this company wont survive, that's why they are getting it and a lot of it. They need it to pay not only the management of the company but also to acquire new information, data, tools and people that specialize in psychedelics which can costs millions of dollars, specially when they have to acquire other small companies for these resources. Anyway, I am here to give you all another possible hit point we can achieve by holding this stock. I predict the stock to reach up to 10$ per share on NASDAQ announcement and 20$ on NASDAQ opening. There is still place of growth and while the stock now at 4.5$, it is still a green go to buy it. The worst already behind, the stock stabilized at price of 4$ and will have a good checkpoint to start rising from. The NASDAQ news is still unknown but lets hope it will come soon, I'd say maybe maximum 2 months of waiting. I bag-hold myself already 14000 shares from 1$ and still wait for the NASDAQ news. Another tip I would recommend to people who can afford less, buy TRIP, I can't say their reliability for long term but the stock is super cheap at 0.38 cents a share and if MMED will rise up, TRIP will be on its back rising the double. Good luck mates.
MLong
by DumpItAgain
4
MMED, The Second Psychedelic Stock That Will Reach NASDAQAs some of you have witnessed CMPS IPO climb from 17$ to 43$ in 3 days, most of investors wonder what is the next psychedelic stock that will perhaps result in the same behavior. Of course, a lot of stocks from the psychedelic sector are still penny stocks and mostly Canadian stocks. Penny Stocks are a scary investment to some of you and I completely can relate and understand this. However, remember that around 3-5% of Penny Stocks still can be valuable stocks. But in any case, I am not here to convince you to invest in Penny Stocks or not, I am here to predict which one will rise and will have a very promising returns. The stock that I predict a strong rise called MMED or Mind Medicine, A Canadian penny stock traded on NEO exchange. The stock is a small cap, around 325 Million Dollars. Which leaves us a lot of space for a good long term rise. The stock by the time I write is around a 1.09$ and I am riding this stock from July, where it was around 0.45$. Around 6 weeks ago, MMED announced a NASDAQ up-listing, and rumors speculate that MMED will do a reverse split 4:1 in order to get the minimum price 4$ to be able to up-list on NASDAQ. In my experience, the stock is very reactive to news and rumors, and any announce of good news, will drive the stock 10% up minimum easily. Most of USA investors are not allowed to invest in Penny Stocks from any other exchange than NASDAQ, this is a good opportunity to buy this stock now and retail it on the NASDAQ up-listing to other investors. Of course, everything has a risk, and as MMED says, they do not guarantee to be accepted by NASDAQ, but once there is a confirmation, this stock will very bullish until the date to up-listing. I predict the price will hit minimum 2$ a share before NASDAQ, and once we up-list on NASDAQ, whether there was a reverse split or not, the day of up-listing will drive the stock minimum from 150% to 300% or more. Edit: I do not take responsibility for any of your investment, strong return always represents a strong risk.
MLong
by DumpItAgain
5
PRMO.C - New psychedelic play with $1.5M mkt cap & 10M float!This one could easily multi-bag just by virtue of being too cheap at $1.5M market cap and super tight 10M float. Announced entering psychedelics space today but also has Health Canada license for PPE distribution. Multiple potential catalysts looming... Primo Nutraceuticals Inc., Engages MedCan Biotechnologies to Conduct Chemo typing & Geno-typing Studies of Psilocybin Mushrooms VANCOUVER, British Columbia, Oct. 14, 2020 (GLOBE NEWSWIRE) -- PRIMO NUTRACEUTICALS INC. (CSE: PRMO) (OTC: BUGVF) (FSE: 8BV) (DEU: 8BV) (MUN: 8BV) (STU: 8BV) ("PRIMO" or the "Company") Primo Nutraceuticals Inc. has entered intoa non-binding letter of intent (the "LOI") with MedCanBiotechnologies Inc. (“MEDCAN BIOTECH”). MEDCAN BIOTECH will act as a consultant to conduct a chemo typing (Chemical Analysis) and a genotyping (Genetic Analysis) study of up to 5 strains of Psilocybin mushrooms (commonly known as Magic Mushrooms). Terms of Engagement Health Canada (HC) has recently shifted towards psychedelic-assisted psychotherapies in safe, controlled environments as acceptable treatment options. Pursuant to Section 56 exemption from the Canadian Drugs and Substances Act to treat anxiety associated diagnoses,MEDCAN BIOTECH will apply to Health Canada to receive approval under the Controlled Drug and Substances Act to allow MEDCAN BIOTECH to conduct research in order to effectively standardize the extraction of psilocybin from mushrooms. The Health Canada permitby MEDCAN BIOTECHwill allow to develop and license intellectual property (IP) exclusively for further product development by PRIMO via chemo-typing and geno-typing of 5 different mushrooms to understand their properties. MEDCAN BIOTECHwill proceedto patent methods of analysis and results on behalf of PRIMO, whereby data generated will be used in the production of nutraceutical products. All IPand products developed as a result of the analysis will become the property of PRIMOfor their exclusive use. Psychedelic research focused on psychedelic medicine and psychedelic drugs have demonstrated that these substances have potential for treating ailments including anxiety, addiction, depression, substance dependency, attention deficit hyperactivity disorder and even post-traumatic stress disorder.The data produced can be used to generate premium natural health mushroom nutraceutical products. Genotyping can be used for the identification and labeling of different varieties of psilocybin mushrooms.
PLong
by wealth_bakery
1
Potential descending channel for MMED?The green upward sloping line of support is potentially keeping a bullish flag in play here, but it appears as though downward pressure is indicating there may be a retest of the bottom blue channel where I have the red arrow pointing down. KEY TAKEAWAYS A descending channel is drawn by connecting the lower highs and lower lows of a security's price with parallel trendlines to show a downward trend. Traders who believe a security is likely to remain within its descending channel can initiate trades when the price fluctuates within its channel trendline boundaries. A more potent signal occurs with a breakout, which is when a security's price breaches an established channel's boundaries, either on the upper or lower side.
M
by ScotianBot
Shroom Is the New WeedI've been bullish on psychedelic stocks for a while now and I really like this low hanging fruit here, RVV. Fundamentals are good and it is only a question of time before psychedelic medicine penetrates the healthcare sector with undeniable therapeutic properties. Company also boasts a nice pharma play imo. Technical (*resolution may affect drawings*): Interesting support on Fibonacci arcs . Bullish candles on (A), (B), and (C). (A) failed although it broke a bearish sequence. The stock reached support again between (B) & (C) at around $0.17. Looking forward to see what happens at the 0.786 arc (D) - but everything seems to indicate we have support if anyone thinks of jumping in now. Still cheap imo , but a pullback in the $0.20-0.25 wouldn't be surprising. Hopefully a nice catalyst is going to surface in the next weeks in order to propel the stock over the current resistance level (~$0.385). If not end of July (D) maybe end of summer. Please know this is only my opinion and I am not a financial advisor. Feel free to drop comments! Cheers
CSE:RVVLong
by Chasseur-Cueilleur
2
SHRM.C — Signs of bottoming out with breakout likelySHRM.C is the leader in the emerging psychedelics/mental health treatment sector. Recent pullback from the $2.40 high presents a nice opportunity, in my opinion. Tested $1.10 twice and appears to have found the bottom with hourly MACD/RSI suggesting it is about to breakout. Positive news flow. Expected to announce closing of $10M financing this week. More news with regards to their North American expansion plans expected soon as well.
SLong
by wealth_bakery
1
NUMI.V - New major player in the hot psychedelics sectorNUMI.V is one of the more legit entries into the psychedelics space with a controlled substance license and healing centre in Vancouver. Roughly 34M shares trading atm with the rest locked up for the foreseeable future. Good action today, forming the base around $1 with VWAP of $1.08. Expecting further appreciation in the coming days before it pauses for consolidation. Top volume on TSX-V today. Many brokerages did not have it available for trading, so there will be new buyers lining up tomorrow and Friday. $2 is a realistic near-term target, in my opinion, given the hot sector and promotion.
NLong
by wealth_bakery
1
LITT.V -- Signs DA for a Psychedelics Clinic in CaliforniaThe psychedelics/psilocybin sector is heating up again. MMED.N has gained 100%+ off recent lows and SHRM.C is hitting fresh highs. Not many people know this but LITT.V is a strategic investor in SHRM.C and today it had a significant announcement of its own... Technical chart is a thing of beauty! Strong accumulation with bullish MACD/RSI/Stoch action. Lots of room to run! -------------------------------------------------------------------------------------------------------------------------------- Roadman Investments Signs Definitive Agreement with Psychedelic Insights Solidifying Psychedelics Clinic Investment March 31, 2020 - TheNewswire - VANCOUVER, British Columbia – Roadman Investments Corp. (TSXV:LITT) (FWB:1QD) (OTC:RMANF) (“Roadman Investments” or the “Company”) is pleased to announce the signing of a definitive agreement with Psychedelic Insights to form a joint venture for the purpose of opening up a legal psychedelic treatment center in the state of California upon the legalization or medical approval of psilocybin. Psychedelic Insights is one of the only companies in the world that offers psychological guided psychedelic experiences with magic psilocybin truffles in their safe psychedelic space in the center of Amsterdam. The company has experienced specialists, a passion for healing people, proven results, mature IT marketing and sales infrastructure with bookings system, CRM, Mail-systems, Screening evaluation, etc. Psychedelic Insights is perfect partner for Roadman as their business is very scalable across jurisdictions. With the liberalisation of drug policies globally we anticipate the need for qualified certified therapists and practitioners to be a major bottleneck to growth. Psychedelic Insights offers a comprehensive training program that will allow the scale across the US as new states approve treatments. Roadman Investments providing capital and Psychedelic Insights providing the expertise and operating the centers. The number of researchers, universities, and other institutions conducting and publishing scientific studies on the healing powers of psychedelics is increasing daily and is at an all-time high. Stigma is dissolving and people are starting to seek out psychedelic experiences and we expect there to be a lot of demand for these mental health services in the future. California is a great starting point for the first Psychedelic Insights Center in the US as the state is very progressive, has the most cities that decriminalized psilocybin in the country and has the largest population. Definitive Agreement Terms - Roadman shall contribute up to $500,000 USD to the partnership in order to launch the center’s operations, which the Company will source from financing or selling of assets. - Roadman Investments and Psychedelic Insights are jointly responsible to manage finances, arranging insurance and deposits, creating a budget, managing expenses and creating financial reports. - Psychedelic Insights shall contribute to establishing the center’s requirements, protocols, patient intakes, promotional marketing, supplier sourcing for needed materials, overall logistical coordination and registration. - Psychedelic Insights is responsible for a high-quality business plan at least 5 months prior to the launch of the clinic - Psychedelic Insights is responsible for the coordination and hiring of mental health professionals to operate the center. Exclusivity Psychedelic insights grant Roadman Investments a 36-month period of exclusivity for the state of California. Neither Psychedelic Insights nor any of its representatives will, at any time solicit, encourage, discuss, negotiate or entertain any proposals from or provide financial, operating or any other non-public information to, any party other than Roadman with respect to the subject matter of the proposed partnership. Equity Interests Each Partner shall be entitled to each item of the Partnership's income, profit, gain, loss, cost, deduction, credit or allowance in proportion to its Partnership Interest listed below: - ROADMAN INVESTMENTS CORP: 51% - PSYCHDELIC INSIGHTS: 40% - FLAGSHIP US CLINIC DIRECTOR: 9% CEO and Director Luke Montaine stated: “Psychedelic Insights is currently one of the few operational psychedelic clinics in the world and have an amazing team that is helping people achieve personal transformations with psychedelics. This agreement will allow both companies to launch, when legally permitted to, and capture a first mover advantage in the country.” In addition, we advise that the Company will be required to secure financing of equity or debt, sell investment assets and/or seek alternative financing methods in order fund the fulfillment of the above disclosed obligations. There is risk that the license or approval for planned treatment center may not be obtained and that if approval is not obtained the Psychedelic Insights Center and joint venture will not exist.
LLong
by wealth_bakery
MMED day 1 121%Mind Med is the first psychedelic company to IPO. Backed by big names from big brands, Shark Tank and Tom's Shoes and Canopy Growth. MMED has in its portfolio (1) psychedelic-derived drug for the treatment of opiate addiction made from indigenous African plant iboga used in religious rituals for thousands of years (2) LSD microdosing trials. + 10x potential. - Most private sale investors have no lockup. Last week the company did a pre-IPO round at $0.33 for about $24M
M
by jhudson2
1
LITT.V - Potential breakout brewing on 12M volume & growing bidsSpeculative $5M mkt cap psychedelic mushrooms & Coronavirus spread prevention pharma play. Mostly promo driven but cheap mkt cap given recent developments. - Feb 5, 2020: Signed LOI with Legal Dutch Psilocybin Therapy Center to create JV in California. Expecting to sign DA at the end of February. - Feb 12, 2020: Signed LOI with CLOV Biopharma (specializing in research of cedar leaf oil vapour to prevent the spread of Coronavirus and other pathogenic respiratory viruses). Should be close to done churning through .055 pp shares and profit takers from recent lows. Strong bid support. Today's 12M+ volume was 2nd highest on TSXV and is a potential sign of coming breakout.
LLong
by wealth_bakery